rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 144 145 146 147 148 ... 179 »» | Laatste | Omlaag ↓
  5. [verwijderd] 5 juli 2007 19:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    het duurt nooit langer dan twee weken dat er nieuws komt....dus uiterlijk woensdag volgende week weer iets gezelligs?

    dan bedoel ik niet poster presentation :)
  9. [verwijderd] 9 juli 2007 14:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Spread of bird flu to humans only “matter of time
    Monday, 12 June 2006, 9:51 am
    Press Release: University of Auckland

    Spread of bird flu to humans only “matter of time”

    An Australian expert on the flu virus has warned that it is only a matter of time that one of the present strains of bird flu will jump species and be spread from human to human.

    However, Dr Jose Varghese, Chief Research Scientist of the Division of Molecular and Health Technologies at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Melbourne, says both New Zealand and Australia are well-prepared to handle any outbreak.

    SEARCH NZ JOBS

    Scoop VIDEO & AUDIO

    MORTGAGE Calculators

    Scoop MEDIA TRACKING

    Scoop NEWS by TOPIC

    Dr Varghese, who was visiting the national Centre for Molecular Biodiscovery, hosted by The University of Auckland, said all global flu pandemics had avian origins.

    “We are worried of course that the virulent avian strain that has been killing people recently will eventually become ‘humanised’ and jump the species. I guess it’s just a matter of when, not if.

    “The current theory is that farm animals, typically pigs, become infected with both an avian and a human flu strain at the same time. The two viruses exchange genes in the animal host and produce a human adapted virus.”

    Dr Varghese determined the structure of a surface enzyme (neuraminidase) of the influenza virus with a CSIRO colleague, Dr Peter Coleman, in 1983, leading to the development of a new class of anti-viral drugs in the late 1990s which are potent inhibitors of the enzyme.

    The first of these, the drug, Relenza ™ was developed by CSIRO and Biota Holdings Ltd using structure-based drug design methods, based on the three dimensional atomic structure of neuraminidase. The drug was then taken to clinical trials by Glaxo Pharmaceuticals.

    The drug Tamiflu ™ was developed later in the United States based on the structural work of the CSIRO group and the lead compounds subsequently identified for new drug development.

    Both drugs target a small “pocket” in the surface enzyme, neuraminidase, which is identical in every strain of influenza, making them effective against all strains and sub-types of influenza irrespective of their origin.

    These drugs can also be used prophylactically to prevent the spread of infection if used early in an outbreak. As both drugs act as a molecular “plug” which prevents the virus replicating, they also shorten the duration of the illness, enabling more effective management and treatment.

    Dr Varghese says because the flu virus can mutate rapidly, flu vaccines are only effective against known strains of influenza and cannot deal effectively with emerging strains, particularly those that arise during global pandemics.


    “The fact that we now have these anti-viral drugs that work against whatever strain of flu is around is a big bonus. We also learnt a lot from the SARS epidemic – that if we get to the places where an infection is breaking out and contain it quickly, we are able to control these diseases.”

    The possibility of emerging drug resistance to the neuraminidase inhibitors is being closely monitored by the CSIRO, says Dr Varghese.

    “We‘re finding very little drug resistance at present, but we are watching what we consider may be a weak link in Tamiflu ™. Unlike Relenza ™, to work, Tamiflu ™ depends on the viral neuraminidase itself making an internal change. This provides an opportunity for the influenza virus to mutate to stop that happening.”

    Dr Varghese says the methodology which led to the design of the anti-viral neuraminidase inhibitors has huge potential for new drug development and technologies to combat other infectious diseases, and major killers such as cancer, heart disease and diabetes.

    “Structural biology – that is our understanding of how proteins work at a molecular level – has revolutionised biology. It is a discipline that has grown exponentially in the last 20 years and will make a huge contribution to medical science this century.

    “By understanding protein structures and how processes work at a molecular level, we can manipulate and modulate biological systems and avoid the hit and miss approach we have used in the past to develop new drugs.”

    Structure-based drug design, says Dr Varghese, overcomes the lack of specificity of drugs developed by traditional, high through-put, chemical screening.

    “One of the problems with the traditional approach is that we know certain compounds inhibit certain functions, but we don’t know if other processes in the body are being affected. The benefit of structure-based drug design is that we can design a drug, like these anti-viral drugs, that is exquisitely selective.”

    The Centre for Molecular Biodiscovery is one of seven national centres of research excellence established by the Government in 2002 to drive new drug development and technologies to combat major diseases in New Zealand. It is taking a leading role in post-genomic science by merging traditional scientific disciplines to improve human health.

    -ends-


  18. [verwijderd] 10 juli 2007 14:46

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology Announces New Licensing Agreement for Generex Oral-lyn
    Tuesday July 10, 8:00 am ET


    WORCESTER, Mass., July 10, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into an exclusive Product Licensing & Distribution Agreement with the Armenian Development Agency (ADA) (http://www.ada.am) and Canada Armenia Trading House Ltd. (CATH) for the commercialization of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, in the Republic of Armenia, Georgia, and the Republic of Kazakhstan. ADA and CATH will bear any and all costs associated with the procurement of governmental approvals for the sale of the product, including any clinical and regulatory costs.
  20. [verwijderd] 10 juli 2007 15:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    betekent dit dat oralin nu toegelaten wordt op de markt in Georgie, Armenia en Kazachstan???

    oftewel goedkeuring?

    of is het ´selchts ´ een distributie overeenkomst , maar moet eerst de goedkeuring toelating markt nog komen?

    iemand?
3.572 Posts
Pagina: «« 1 ... 144 145 146 147 148 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.670
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.678
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.850
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.337
Air France - KLM 1.025 35.045
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.854
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.233
AMG 971 133.355
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.714
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.108
ASML 1.766 107.414
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392